JP2024156779A5 - - Google Patents

Info

Publication number
JP2024156779A5
JP2024156779A5 JP2024122975A JP2024122975A JP2024156779A5 JP 2024156779 A5 JP2024156779 A5 JP 2024156779A5 JP 2024122975 A JP2024122975 A JP 2024122975A JP 2024122975 A JP2024122975 A JP 2024122975A JP 2024156779 A5 JP2024156779 A5 JP 2024156779A5
Authority
JP
Japan
Prior art keywords
cancer
component
pharmaceutically acceptable
acceptable salt
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024122975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024156779A (ja
Filing date
Publication date
Priority claimed from JP2023078608A external-priority patent/JP7531656B2/ja
Application filed filed Critical
Publication of JP2024156779A publication Critical patent/JP2024156779A/ja
Publication of JP2024156779A5 publication Critical patent/JP2024156779A5/ja
Pending legal-status Critical Current

Links

JP2024122975A 2022-05-11 2024-07-30 化合物及びその使用 Pending JP2024156779A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263340927P 2022-05-11 2022-05-11
US63/340,927 2022-05-11
JP2023078608A JP7531656B2 (ja) 2022-05-11 2023-05-11 化合物及びその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023078608A Division JP7531656B2 (ja) 2022-05-11 2023-05-11 化合物及びその使用

Publications (2)

Publication Number Publication Date
JP2024156779A JP2024156779A (ja) 2024-11-06
JP2024156779A5 true JP2024156779A5 (cg-RX-API-DMAC7.html) 2026-05-18

Family

ID=86732694

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023078608A Active JP7531656B2 (ja) 2022-05-11 2023-05-11 化合物及びその使用
JP2024122975A Pending JP2024156779A (ja) 2022-05-11 2024-07-30 化合物及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023078608A Active JP7531656B2 (ja) 2022-05-11 2023-05-11 化合物及びその使用

Country Status (17)

Country Link
US (2) US12139487B2 (cg-RX-API-DMAC7.html)
EP (1) EP4522280A1 (cg-RX-API-DMAC7.html)
JP (2) JP7531656B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250024923A (cg-RX-API-DMAC7.html)
CN (1) CN119677738A (cg-RX-API-DMAC7.html)
AR (1) AR129299A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023270055A1 (cg-RX-API-DMAC7.html)
CA (1) CA3252955A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024003450A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024015229A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2024000231A (cg-RX-API-DMAC7.html)
IL (1) IL316531A (cg-RX-API-DMAC7.html)
JO (1) JOP20240250A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013838A (cg-RX-API-DMAC7.html)
PE (1) PE20250261A1 (cg-RX-API-DMAC7.html)
TW (2) TW202506693A (cg-RX-API-DMAC7.html)
WO (1) WO2023220219A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3198317A1 (en) * 2020-11-10 2022-05-19 Kevin J. Wilson Compounds and uses thereof
WO2025008060A1 (en) * 2023-07-05 2025-01-09 Janssen Pharmaceutica Nv 1,6-naphthridine compounds as smarca2 inhibitors useful for the treatment of smarca4 deficient cancers
WO2025099307A1 (en) * 2023-11-10 2025-05-15 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of diseases
US20250304542A1 (en) * 2024-03-11 2025-10-02 Enanta Pharmaceuticals, Inc. Fused Heterobicyclic Antiviral Agents
WO2025209520A1 (zh) * 2024-04-03 2025-10-09 深圳众格生物科技有限公司 一种化合物、包含其的药物组合物及其用途
WO2025237242A1 (zh) * 2024-05-14 2025-11-20 上海和誉生物医药科技有限公司 一种smarca2抑制剂及其应用
CN118930537B (zh) * 2024-07-23 2025-05-13 上海信诺维生物医药有限公司 一种抑制brm的化合物
CN118930561B (zh) * 2024-07-23 2025-04-08 上海信诺维生物医药有限公司 一种稠环化合物
CN118908980B (zh) * 2024-07-23 2025-04-08 上海信诺维生物医药有限公司 一种多环化合物
WO2026046365A1 (zh) * 2024-08-30 2026-03-05 上海齐鲁制药研究中心有限公司 Smarca2抑制剂及其制备方法和用途
WO2026057002A1 (zh) * 2024-09-12 2026-03-19 江苏恒瑞医药股份有限公司 一种烯炔类化合物及其应用
WO2026061424A1 (zh) * 2024-09-18 2026-03-26 深圳众格生物科技有限公司 一种化合物、包含其的药物组合物及其用途
WO2026131996A1 (en) * 2024-12-17 2026-06-25 Onco3R Therapeutics Bv Fused azines for the treatment of cancer
WO2026158636A1 (zh) * 2025-01-26 2026-07-30 江苏恒瑞医药股份有限公司 一种三环骨架芳酰胺类化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007243466B2 (en) 2006-04-26 2012-01-19 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2015095788A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
SG10201900631TA (en) 2014-08-01 2019-02-27 Nuevolution As Compounds active towards bromodomains
BR112022015110A2 (pt) 2020-01-29 2022-11-08 Foghorn Therapeutics Inc Compostos e usos dos mesmos
BR112022015109A2 (pt) * 2020-01-29 2022-11-08 Foghorn Therapeutics Inc Compostos e usos dos mesmos
WO2021155264A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155262A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
CA3198317A1 (en) 2020-11-10 2022-05-19 Kevin J. Wilson Compounds and uses thereof

Similar Documents

Publication Publication Date Title
JP2023512039A5 (cg-RX-API-DMAC7.html)
Wang-Gillam et al. Defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment refractory pancreatic cancer: a phase I dose escalation and expansion study
Patnaik et al. A first-in-human phase I study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 dimesylate), in patients with advanced cancer
JP2023168298A5 (cg-RX-API-DMAC7.html)
JP2023512038A5 (cg-RX-API-DMAC7.html)
AU2018288060A1 (en) IL-1beta binding antibodies for use in treating cancer
JP2022082565A (ja) がんを処置するための方法
JP2020515578A5 (cg-RX-API-DMAC7.html)
JP2022533578A5 (cg-RX-API-DMAC7.html)
Oostendorp et al. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors
JP2023507190A5 (cg-RX-API-DMAC7.html)
JP2024529976A5 (cg-RX-API-DMAC7.html)
CN107148285A (zh) 吡咯并苯并二氮杂*‑抗体缀合物
RU2016146993A (ru) Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака
JP2010523477A5 (cg-RX-API-DMAC7.html)
AR040367A1 (es) Anticuerpos humanizados contra el receptor de linfotoxina beta
ES2897782T3 (es) Método de tratamiento de las enfermedades de la metástasis ósea, medicamentos para el tratamiento y método para predecir el resultado clínico del tratamiento de las enfermedades causadas por metástasis ósea
Lupp et al. Reevaluation of sst1 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-7
WO2020032231A1 (ja) 免疫チェックポイント阻害薬の有効性を予測するためのバイオマーカー
IL273387B1 (en) Thylanstatin analogs
JPWO2022270524A5 (cg-RX-API-DMAC7.html)
Draghici et al. Paraneoplastic syndromes in digestive tumors: A review
JP2020521786A5 (cg-RX-API-DMAC7.html)
HK1223547A1 (zh) 癌症治疗方法
Alvarez et al. Sensitivity of monoclonal antibodies to carcinoembryonic antigen, tissue polypeptide antigen, alpha-fetoprotein, carbohydrate antigen 50, and carbohydrate antigen 19-9 in the diagnosis of colorectal adenocarcinoma